(Health-NewsWire.Net, August 26, 2016 ) It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020. Currently, drugs for the prevention and treatment of osteoporosis are mainly categorized into bone resorption inhibitor which includes diphosphonate (alendronate, etidronate and risedronate), sex hormone, calcitonin, selective estrogen receptor modulator and bone formation promoter, fluoride product, vitamin D and calcium preparation, parathyroid hormone included. Request sample at : https://marketreportscenter.com/request-sample/133420
As a member of the new generation of osteoporosis drugs, risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate sodium has brought in a large amount of sales value in the global market, for example, over USD 1 billion in 2004. According to CRIs market survey, risedronate sodium develops fast after appearing in the Chinese market, annual sales value in sample hospitals rising from less than 40,000 in 2008 to CNY 9.71 million in 2014 and CAGR during this period reaching 156%. Risedronate sodiums in the Chinese market are all produced by local enterprises represented by Kunming Jida Pharmaceutical Co., Ltd, Topfond, Yangtze River Pharmaceutical Group, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd and Beijing SL Pharm, among which Kunming Jida Pharmaceutical Co., Ltd has the largest market share of 84% for sales value in 2014. With the ageing population, the incidence of osteoporosis will continue to grow. Therefore the market size of risedronate sodium is expected to keep expanding fast in the next few years in China.
Check for Discount at : https://marketreportscenter.com/request-discount/133420 Readers can get at least the following information from this report: -market size of risedronate sodium in China -competitive landscape of risedronate sodium in Chinese market -price of risedronate sodium made by different enterprises in China -market outlook of risedronate sodium in China
The author suggests the following groups of people purchase this report: -manufacturers of osteoporosis drugs -investors/ research institutions interested in Chinese medicine market -any interest in the Chinese medicine market, please contact CRI for customized survey service
Browse full report with TOC : https://marketreportscenter.com/reports/133420/investigation-report-on-china-risedronate-sodium-market-2010-2019
Connect for more details: Sam Collins Market Reports Center Call us : 1-646-883-3044 (US) Email : info@marketreportscenter.com visit our website : https://marketreportscenter.com
Market Reports Center
Sam Collins
1-646-883-3044
sam@marketreportscenter.com
Source: EmailWire.Com
|